Alternative splicing contributes to the vast complexity of mRNA transcripts and protein isoforms. It has been estimated that the majority of protein-coding genes are subject to alternative splicing in humans. Alternative splicing plays a critical role in physiological processes and cell development programs, and dysregulation of alternative splicing is often associated with pathologic conditions such as cancer. Indeed, the abnormal splicing is frequently found in lung cancer, which produces various protein isoforms with properties that may have different functions and therefore even diverse effects on tumor malignant development. In this highlight, we summarize the evidence supporting the functional role of alternative splicing in lung cancer, discuss the regulation of alternative splicing, and highlight the relevance of splicing variation on lung cancer therapy.
Introduction
Alternative splicing is a mechanism for increasing protein diversity through modulating specific exon recombination during post-transcriptional processing of a transcript. Alternative splicing has essential roles in cell homeostasis and cellular processes. Growing evidence shows that deregulation of splicing is often associated with pathologic conditions such as cancer [1] [2] [3] . The abnormal splicing is frequently found in lung cancer. Consequently, the studies indicate that alternatively spliced proteins are particularly relevant in lung cancer cell growth, migration and metastasis, which will be discussed in detail below.
Roles in regulation of cell proliferation and migration
The RNA-binding protein Quaking (QKI) as a critical regulator of splicing in lung cancer is frequently down-regulated [4] . QKI-5 regulates the alternative splicing of NUMB through binding to two RNA elements of NUMB pre-mRNA, which in turn suppresses cell proliferation and blocks the activation of the Notch signaling pathway. The reduced QKI abundance is strongly associated with poorer prognosis [4] , and low-level nuclear QKI in non-small cell lung cancer (NSCLC) is an independent prognostic factor for disease-free survival [5] . Another study has demonstrated that RNA binding motif protein RBM5 and its homologous RBM6/10 antagonistically regulate NUMB exon 9 alternative splicing to control tumor cell proliferation and xenograft tumor growth [6] . RBM10 mutations identified in lung cancer
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cells disrupt NUMB splicing regulation and promote cell growth [6] . The well-known splicing regulators hnRNP A1 and A2 (heterogeneous nuclear ribonucleoproteins) modulate expression of Tid1 isoforms in NSCLC [7] . The authors reported that RNAi-mediated depletion of hnRNP A1/A2 increased the expression of Tid long form, inhibited cell proliferation and attenuated EGFR signaling.
Alternatively spliced proteins play a pivotal role in regulation of cell migration. For example, transplantation of a CD44v-positive subpopulation of 4T1 breast cancer cells in mice induced efficient lung metastasis [8] . CD44v8-10 isoform is dominantly expressed in NSCLC, while non-tumorous tissues principally express CD44 standard (CD44s) and small cell lung cancer tissues express either CD44s or no detectable CD44 [9] . These results indicate that CD44v8-10 might be practically utilized as a diagnostic marker for NSCLC. Yae's work established that epithelial splicing regulatory protein 1 (ESRP1) regulated the expression of CD44v [8] . Down-regulation of ESRP1 in CD44v-positive cells results in an isoform switch from CD44v to CD44s, leading to reduced cell surface expression of xCT and suppression of lung colonization [8] . Although much is known about the suppressor role of P53 and its regulation, the alternative splicing of P53 is not well understood. A recent study described an alternatively spliced form of P53, P53Ψ, which uses an alternative 3' splice site in intron 6 [10] . P53Ψ was detected in approximately 22% of early stage adenocarcinomas, and patients with tumors expressing P53Ψ displayed a decrease in overall survival compared with the P53Ψ negative patients. P53Ψ does not transactivate canonical P53 target genes, while it attenuates E-cadherin expression, induces those markers of the epithelial-mesenchymal transition (EMT), and consequently increases the motility and invasive capacity of lung cancer cells [10] . Different isoforms of neuropilins (NRP1 and NRP2) are generated by alternative splicing. NRP2a and NRP2b present different functions in lung cancer. NRP2b enhances cellular migration, invasion and tumorsphere formation in lung cancer cells in response to TGFß signaling, and promoted metastasis in xenograft mouse models [11] .
The role of SRPK1 in the maintenance of cancer stem cell-like phenotype Splicing factors are also shown to be involved in the maintenance of cancer stem cell features. For example, the splicing factor serine-arginine protein kinase 1 (SRPK1) has been reported to stimulate a stem cell-like phenotype in human NSCLC [12] . Gong et al found that SRPK-transduced cells expressed higher levels of pluripotency-associated markers and greater self-renewal capacity [12] . Further they performed gene knockdown experiment to suppress expression of SRPK and demonstrated the converse effect. The in vivo experiments on BALB/c nude mice showed that tumors produced by SRPK1-transduced NSCLC cells were larger than those formed by control cells, suggesting that SRPK1 promotes stem cell accumulation.
EGF signaling and alternatively spliced genes
To identify oncogenesis genes in lung cancer, we performed exon array analyses of clinical specimens from adenocarcinomas and squamous cell carcinoma. We discovered many novel alternatively spliced genes such as SPAG17 (5' deletion), VAV3 (5' deletion) and BMX∆N [13, 14] . We performed 5' RACE or 3' RACE followed by Sanger sequencing to confirm these new isoforms. BMX∆N lacks the N-terminal sequence from exon 1 to exon 8. BMX∆N only expresses in lung cancer but not in paired non-cancerous tissues. Based on its function in promoting cell growth, cell migration and oncogenic transformation we suggested that BMX∆N might play important roles in lung tumorigenicity. Interestingly, BMX∆N is strongly associated with EGFR mutation in these specimens [14] . Previous studies showed that EGF signaling could induce alternative splicing. In Zhou's work [15] , they demonstrated that Akt-SRPK-SR axis constitutes a major branch in transducing EGF signaling to regulate splicing program in the nucleus. A recent work reported that EGF-induced ubiquitylation of a well-known splicing regulator, hnRNP A1 together with the activation of SRPKs results in the upregulation of Rac1 splicing isoform, Rac1b, to promote cell motility [16] . We speculate that BMX∆N might be the EGF signaling pathway-induced splicing event in lung cancer. Although we found its function may be due to increased activation of ERK, the exact mechanism that drives the activation also remains to be elucidated.
Alternatively spliced genes as therapeutic targets in lung cancer
MET exon 14 skipping and MET activation have been revealed in lung cancer [17] [18] [19] . NIH3T3 cells harboring MET exon 14 splicing alterations are sensitive to MET inhibitors. Further clinical trial reported that three patients with MET exon 14 alternative spliced variant in lung or histiocytic sarcoma tumors showed durable response to MET-targeted therapies. The patients were treated with crizotinib or capmatinib for 4-5 months or 13 months with tumor reduction of 60%, 53%, and 61%, respectively [19] . The kruppel-like zinc finger transcription factor (KLF6) generates at least four alternatively spliced isoform. Kruppel-like factor splice variant 1 (KLF6-SV1) is an oncogenic splice of the KLF6 tumor suppressor gene that was found to be overexpressed in a number of human cancers including lung cancer [20] . Increased expression of KLF6-SV1 contributes to chemo-resistance in lung cancer. Targeted reduction of KLF6-SV1 by RNA interference results in the induction of spontaneous apoptosis in cell culture synergizes with chemotherapeutic agents like cisplatin, and lead to significant tumor regression in vivo [21] . These observations emphasized the importance of investigation of alternative splicing genes in lung cancer for improving targeted therapy.
Conclusions
Genome-wide analyses including microarrays and RNA-seq accelerate the identification of cancer-associated splice variants. For example, Li et al generated alternative splicing profiles in lung adenocarcinoma and lung squamous cell carcinoma patients in TCGA by using RNA-seq data [22] . They demonstrated that a total of 3691 and 2403 alternative splicing events were significantly correlated with patient survival in lung adenocarcinoma and lung squamous cell carcinoma, respectively, including PIK3C3, RRAS2, and FGFR2. Because the isoforms are usually functionally distinct, the detailed study about a direct role of these alternatively spliced proteins as drivers of cancer development is necessary. The commonly observed transcript variants may also possess a normal physiological function, thus identification of genes with tumor-specific splicing is also needed. In conclusion, future studies in alternative splicing not only help to identify diagnostic marker may also help to develop targeted therapies.
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